<DOC>
	<DOCNO>NCT01582438</DOCNO>
	<brief_summary>The purpose study provide sildenafil therapy subject complete A1481156 study treatment Pulmonary Arterial Hypertension ( PAH ) India judge Investigator derive clinical benefit continue treatment sildenafil citrate . Sildenafil citrate supply treatment Pulmonary Arterial Hypertension ( PAH ) subject continue derive benefit treatment . The treating physician ( sponsor ) responsible report serious adverse event .</brief_summary>
	<brief_title>An Open Label Access Study For Subjects Who Completed A1481156</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Subjects complete study A1481156 judge Investigator derive clinical benefit continuous treatment sildenafil citrate therapy . Subjects pulmonary arterial hypertension ( PAH ) treat study site India Subjects willing able comply schedule visit , treatment plan , study procedure Pregnant lactate female subject . Current participation study study participation , except A1481304 followup period . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>